前列腺穿刺活检标准与结局的长期趋势:达特茅斯经验
该研究回顾性分析2011年1月至2016年3月在达特茅斯-希区柯克医学中心接受前列腺穿刺活检的614例患者,评估2012年前后保守筛查实践下的活检与癌症诊断趋势。结果显示活检时PSA随时间升高(2011年7.2 vs 2015年10.1,P=0.0085),低级别病变比例下降而中高级别病变比例上升(2011年 vs 2015年:Gleason 3+3为21.1% vs 10.8%,≥Gleason 3+4为32.9% vs 43.3%,P=0.0454)。作者认为需要额外研究以确保这些趋势对医疗质量产生有利影响。
要点
- 活检时PSA从2011年7.2升至2015年10.1(P=0.0085),年龄无变化。
- 低级别病变比例下降,中高级别病变比例上升(P=0.0454)。
- 直肠指检异常(OR 2.19)、PSA较高(OR 1.09)和较晚的活检日期(OR 1.01)与更高级别病变相关。
核心结论
- 在基线筛查实践保守的环境中,前列腺穿刺活检标准和结局发生了转变,即活检PSA阈值上升,低级别病变诊断减少50%。
- 作者认为需要额外研究以确保这些趋势对医疗质量产生有利影响。
研究设计与样本
- 回顾性分析2011年1月至2016年3月接受前列腺穿刺活检的患者,按时间分析人口学和临床特征,并用多变量分析评估与更高级别癌症相关的因素。
- 共实施614例前列腺穿刺活检。
主要发现
- 活检时PSA随时间升高(2011年7.2 vs 2015年10.1,P=0.0085),年龄无变化。
- 良性发现比例保持稳定;低级别病变比例下降,中高级别病变比例上升(2011年 vs 2015年:Gleason 3+3为21.1% vs 10.8%,≥Gleason 3+4为32.9% vs 43.3%,P=0.0454)。
- 预测更高级别病变的因素包括直肠指检异常(OR 2.19,P=0.0076)、PSA较高(OR 1.09,P=0.0040)和较晚的活检日期(OR 1.01,P=0.0469)。
关键数值与推荐
- 活检时PSA:2011年7.2 vs 2015年10.1(P=0.0085)。
- Gleason 3+3比例:2011年21.1% vs 2015年10.8%;≥Gleason 3+4比例:2011年32.9% vs 2015年43.3%(P=0.0454)。
- 直肠指检异常与更高级别病变相关(OR 2.19,P=0.0076);PSA较高(OR 1.09,P=0.0040);较晚的活检日期(OR 1.01,P=0.0469)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate trends in prostate biopsy and cancer diagnosis at a center with conservative screening practices in the pre- and post-2012 era. More restrictive prostate-specific antigen (PSA) screening guidelines have led to lower rates of screening, biopsy, and diagnosis of prostate cancer. It is not clear, however, how regions with low baseline screening rates (the Lebanon, New Hampshire hospital referral region centered on Dartmouth-Hitchcock Medical Center had the lowest rate of screening among Medicare patients in 2012) have responded to these guidelines. METHODS: We retrospectively analyzed patients who underwent prostate biopsy from January 2011 to March 2016. Demographic and clinical characteristics were analyzed by time. Multivariable analysis assessed for factors associated with higher grade cancer. RESULTS: There were 614 prostate biopsies were performed. PSA at biopsy increased with time (7.2 in 2011 vs 10.1 in 2015, P = .0085); age did not. There was a stable proportion of benign findings; proportions of low-grade disease decreased, whereas intermediate- and high-grade disease increased (2011 vs 2015: 21.1% vs 10.8% Gleason 3 + 3, 32.9% vs 43.3% ≥ Gleason 3 + 4, P = .0454). Factors predictive of higher grade disease included abnormal digital examination (odds ratio [OR] 2.19, P = .0076), higher PSA (OR 1.09, P = .0040), and later biopsy date (OR 1.01, P = .0469). CONCLUSION: In an environment of conservative baseline screening practices, there has been a shift in prostate biopsy criteria and outcomes, namely a rising PSA threshold for biopsy and a 50% decrease in the diagnosis of low-grade disease. Additional study is needed to ensure these trends are favorably impacting the quality of care.
引用
- Reinstatler L, Rissman C, Seigne JD, et al. Secular Trends in Prostate Biopsy Criteria and Outcomes: The Dartmouth Experience. Urology. 2017. PMID: 28595934. doi:10.1016/j.urology.2017.04.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。